HFS
CTKB icon

Hantz Financial Services’s Cytek Biosciences CTKB Stock Holding History

Hantz Financial Services’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Buy
587
+298
+103% +$1.41K ﹤0.01% 2237
2025
Q4 		$1K Buy
+289
New +$1.34K ﹤0.01% 2311

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hantz Financial Services's CTKB Position: Q1 2026 in Review

Hantz Financial Services increased its Cytek Biosciences (CTKB) stake by 103% in Q1 2026, buying an estimated $1.41K and bringing the position to 587 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Hantz Financial Services first reported a position in CTKB in Q4 2025 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Hantz Financial Services held 587 shares of Cytek Biosciences worth $3K as of Q1 2026.
  • Hantz Financial Services bought 298 Cytek Biosciences shares in Q1 2026, an estimated $1.41K.
  • Cytek Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2237 holding.
  • Hantz Financial Services first reported a position in Cytek Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.